56 Questions
Match the actions with the correct steps for submitting a marketing application for a drug-device combination product:
Conduct testing and submit the change as an amendment = Obtain approval for submission and submit the change in the next annual report Take no action and leave the submission as is = Obtain approval for submission and submit the change in the next annual report Petition the FDA for a stay of action and reconsider = Obtain approval for submission and submit the change in the next annual report Obtain approval for submission and submit the change in the next annual report = Conduct testing and submit the change as an amendment
Match the initial submissions with their appropriate offices for a drug-device combination product:
A Request for Determination to the appropriate review division based on the product’s primary mode of action = A Request for Designation to the Office of New A Request for Designation to the Office of New = A Request for Designation to the Office of Combination Products A Request for Determination to the Office of Pharmacovigilance = A Request for Designation to the Office of Combination Products
Match the recommended action with its corresponding step in submitting a human factor’s validation protocol:
Conduct testing and submit the change as an amendment = Submit the validation protocol for review prior to execution of the study Take no action and leave the submission as is = Submit the validation protocol for review prior to execution of the study Petition the FDA for a stay of action and reconsider = Submit the validation protocol for review prior to execution of the study Obtain approval for submission and submit the change in the next annual report = Submit the validation protocol for review prior to execution of the study
Match the following with their correct requirement for conducting a clinical trial:
Publication copyright statements = Approval from the ethics committee Signed informed consent forms = Approval from the ethics committee Appropriate ICH forms = Approval from the ethics committee Approval from the ethics committee = Approval from the ethics committee
Match the following with their description under Regulation EC 469/2009:
The content and format of the SmPC = The opportunity to obtain an SPC The possibility to obtain protection from gener = The opportunity to obtain an SPC The opportunity to obtain an SPC = The opportunity to obtain an SPC The process for filing a European patent applic = The opportunity to obtain an SPC
Match the following with their role in a non-interventional imposed PASS:
After study commencement, the MAH must submit an = All of the above. Final Assessment by Pharmacovigilance Risk Asses = All of the above. Upon study completion, a final study report with = All of the above. All of the above. = All of the above.
Match the following with their least likely action taken by OPDP in response to promotional communication:
Publication copyright statements = No match Approval from the ethics committee = No match Appropriate ICH forms = No match Signed informed consent forms = No match
Match the following recommendations with the appropriate action:
Recommendation: Be extended to other batches of Drug Product = Action: Further production should be halted until the reason for the discrepancy is identified Recommendation: Be extended to other drug products that may have been associated with the discrepancy = Action: Correct answer Recommendation: No immediate action is needed but the discrepancy should be monitored = Action: Further investigation required Recommendation: Immediate halt of all production activities = Action: Investigate the root cause before resuming production
Match the following retention periods with the appropriate records for each batch of product:
Retention Period: Until the batch expiration date = Records: Production, labeling, and packaging records Retention Period: One year after the batch expiration date = Records: All production, labeling, and packaging records Retention Period: Three years after the batch expiration date = Records: Batch-specific manufacturing records only Retention Period: Five years after the last distribution date for the batch = Records: Distribution and sales reports only
Match the following scenario with the appropriate action:
Scenario: A clinical investigator seeks to treat a critically ill patient not meeting protocol criteria = Action: Proceed with compassionate use protocols Scenario: A clinical investigator wants to use an unapproved drug for a non-serious condition in a clinical trial = Action: Seek approval from regulatory authorities before proceeding Scenario: A patient enrolled in a trial experiences severe adverse reactions to an investigational drug = Action: Report immediately to regulatory bodies and suspend further dosing Scenario: A drug manufacturer discovers a defect in packaging post-distribution = Action: Initiate a product recall and investigate potential impact on patient safety
Match the following actions with the correct steps for preparing a pre-submission meeting for a new drug product:
Book a meeting with health authority = Initiate the meeting scheduling process Compile the documents required for meeting = Gather necessary paperwork for submission Check with internal stakeholders on the readiness = Ensure all required documents are prepared Check on the list of attendees for the meeting = Verify who will be present at the meeting
Match the following considerations with OPDP's role in regulating promotional materials for FDA-approved products:
OPDP will consider whether the promotional material = Review the content of promotional materials OPDP will consider the REMS and boxed warnings = Evaluate safety information in promotions OPDP will consider whether the promotional claim = Assess the accuracy of marketing statements OPDP will take no action as their role is purely advisory = Provide guidance without enforcement powers
Match the following actions with their outcomes related to preparing for a new drug product registration:
Book a meeting with health authority = Schedule an appointment with regulatory officials Compile the documents required for meeting = Organize essential paperwork for submission Check with internal stakeholders on the readiness = Ensure all stakeholders are prepared for submission Check on the list of attendees for the meeting = Confirm who will be participating in the meeting
Match the following actions with the correct response to minimize legal liability:
Gather all pertinent information for a risk-assessment = Top priority for a regulatory specialist Respond to the FDA WL immediately = Immediate action after receiving a Warning Letter Gather all pertinent information and use your 25 = Action not recommended to minimize legal liability Respond without delay to the press reports denying = Inappropriate response to press reports
Match the following scenarios with the correct outcome:
Warning Letter from the FDA regarding adulterated drug = Linked to hundreds of reports of minor AEs Related product reported in press involving legal claim by children = Mothers took medication during pregnancy many years ago Successfully marketed drug for over 20 years without incident = Unexpected legal challenges arise Legal liability concerns for the company = Regulatory specialist's top priority
Match the following terms with their meanings:
Risk-assessment = Process of evaluating potential risks FDA WL = Warning Letter issued by the FDA Press reports denying = Response to media allegations Antihypertensive drugs' efficacy assessment basis according to ICH = Primary assessment criterion
What is the top priority for a regulatory specialist to minimize a company’s legal liability after receiving a Warning Letter from the FDA?
Gather all pertinent information for a risk-assessment and recommend obtaining preliminary legal advice.
What has been linked to hundreds of reports of minor Adverse Events related to a marketed drug product?
Ingredient adulteration
What is the primary basis of assessment for the efficacy of antihypertensive drugs according to ICH?
Blood pressure reduction
What is recommended as the best initial response from a company that has marketed a product successfully for over 20 years without incident but receives a legal claim from children exposed in utero?
Seek legal advice and assess risk.
What action should be taken by a regulatory specialist when press reports involve legal claims related to a product's use during pregnancy many years ago?
Consult with legal experts and assess risks.
In response to an FDA Warning Letter, what should be the immediate action taken by a regulatory specialist?
Gather information for risk assessment and seek legal advice.
When faced with legal liability issues, what should a regulatory specialist prioritize when interacting with the press?
Consult with legal experts before responding.
What should a company do after successfully marketing a drug for over 20 years but facing adverse events and legal claims?
Gather information, assess risks, and seek legal advice.
What should the clinical investigator do based on the expert opinion?
Obtain approval from the CA for compassionate use of the product for this particular patient
What action should the clinical investigator NOT take?
Treat this particular patient with the product
What is the best course of action for seeking feedback on a proposed Phase 3 study design?
Request feedback from the Committee for Medicinal Products for Human Use (CHMP)
What information should be offered related to Scientific Advice during Phase 3 study planning?
Details about patient enrollment criteria
What is NOT a relevant consideration when planning Phase 3 studies?
Packaging and labeling specifications
Which action would be inappropriate during Phase 3 study design planning?
Ignoring feedback from stakeholders
What is a crucial step in obtaining approval for compassionate use of a product?
Following local regulations and ethical considerations
When considering compassionate use, what should be a primary concern?
Ensuring equitable access to treatment
Which option best describes the correct number of patients and study duration?
100 patients for 12 months
What investigational drugs may be shipped to locations from a site in Maryland, USA?
Investigational drugs with or without an IND
Which document outlines whether a serious adverse event in a clinical trial is expected or unexpected?
Investigator's brochure (IB)
If an investigator deviates from the protocol for the second time without harming a patient during an ongoing clinical trial, which action should be taken?
The question does not provide enough information
What is the minimum number of patients required for a clinical trial according to the information provided?
100 patients
Which location is specifically mentioned in the text regarding shipping investigational drugs?
Maryland, USA
According to the information provided, what is the maximum study duration mentioned?
12 months
Which of the following is NOT mentioned as a type of document in the text?
Study protocol
What is the main advice for a clinical trial sponsor regarding the label on a study drug?
Specifying the sites in the EU where the product will be used
What is the recommended action to prove equivalence to the original product when commissioning a clinic?
Conduct bioavailability and bioequivalence studies only
What is required to appear on the immediate container of a study drug?
'Keep out of reach of children' statement
What should a clinical trial sponsor NOT focus on when preparing a label for a study drug?
Including bioavailability and bioequivalence studies information
If conducting a clinical trial, what is crucial for proving equivalence to the original product?
Performing bioavailability and bioequivalence studies
What should a clinical trial sponsor prioritize when labeling a study drug for use in multiple European countries?
'For EU sites' labeling specification
What is a pivotal element to include on the label for a study drug conducted in several European countries?
'Period of use for product' specification
What is NOT necessary on the label of a study drug based on the advice given?
'For sites in the EU' labeling requirement
What is the primary purpose of the ICH (International Council for Harmonisation)?
To discuss and establish common guidelines for safe, effective, and high-quality medicines
Which agency initiated a pilot program to exchange views on scientific issues during the development phase of new medicinal products?
European Medicines Agency (EMA)
In the event of a protocol deviation during a clinical trial, what is the BEST course of action for the monitor?
The monitor reviews the deviation against the trial monitoring plan and takes corrective action
If an investigator deviates from the protocol for the second time without harming a patient, which action should be taken?
The investigator should be provided additional training on protocol adherence
What is the primary basis of assessment for the efficacy of antihypertensive drugs according to ICH guidelines?
Reduction in both systolic and diastolic blood pressure
When faced with legal liability issues, what should a regulatory specialist prioritize when interacting with the press?
Minimizing the company's legal exposure and avoiding further liability
What investigational drugs may be shipped to locations from a site in Maryland, USA?
Drugs approved for marketing or clinical trials in the USA
When considering compassionate use, what should be a primary concern?
The potential for adverse events in the patient
Test your knowledge on the submission process for changes in drug development according to RAC guidelines. Determine the correct actions to take when developing an unapproved drug.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
